If your dog has spent the last few years on a Cytopoint schedule, your vet is about to have a new option to talk about.
On December 31, 2025, the USDA approved Befrena (tirnovetmab), a new monoclonal antibody injection from Elanco for treating canine allergic and atopic dermatitis. According to the American Veterinary Medical Association, Elanco plans to launch Befrena in the first half of 2026 — meaning supply is starting to reach veterinary clinics now. It's the first injectable competitor to Cytopoint (lokivetmab), the once-monthly itch shot that's dominated the canine dermatology market since its 2016 approval.
For the millions of dog owners who watch their dogs lick their paws raw every spring, this is a meaningful shift. Here's what Befrena actually is, how it differs from what your vet is probably already prescribing, and the questions worth asking before you switch.
The size of the canine itch problem
Allergy-driven itching isn't a niche issue — it's one of the most common reasons dogs end up at the vet. According to Elanco's market research, nearly 98% of U.S. veterinarians routinely treat dogs for atopic dermatitis, and itchy dogs make up roughly 20% of the average vet's patient list. The U.S. canine dermatology market is now an estimated $1.3 billion business.
The condition itself is brutal for dogs and exhausting for owners. Cornell's Riney Canine Health Center estimates that atopic dermatitis affects 10 to 15% of dogs, with onset usually between 6 months and 3 years of age. Symptoms typically start with seasonal scratching and can progress into year-round chewing, hot spots, ear infections, and chronic skin damage. Labrador and Golden Retrievers, Bulldogs, West Highland White Terriers, Boxers, Shar Peis, and Shih Tzus are all on Cornell's list of high-risk breeds.
For decades, the standard treatments were steroids, antihistamines, and immunotherapy. Then in the last 10 years, two newer therapies — Apoquel (an oral JAK inhibitor) and Cytopoint (an injectable antibody) — became the go-to options, joined more recently by Numelvi, a new oral allergy pill for dogs the FDA approved in early 2026. Until last week, Cytopoint was essentially the only modern injectable choice for shutting itch down quickly.
What Befrena actually does
Befrena is what's called an anti–IL-31 monoclonal antibody. To translate: IL-31 is a small signaling protein that researchers identified as the main "itch signal" in dogs with atopic dermatitis. When your dog's immune system overreacts to pollen, dust mites, or food allergens, it floods the body with IL-31 — and your dog feels miserable.
A monoclonal antibody is a lab-made protein engineered to grab onto a specific target. Befrena's antibody binds to IL-31 before it can reach a dog's nerve receptors, which is what stops the itch. Cytopoint works the same way — same target, same overall mechanism — which is why they're considered direct competitors.
Per the AVMA, Befrena starts controlling itch within 24 hours of injection and is administered subcutaneously by a veterinarian. Veterinary Practice News reports it was tested in dogs of any age, with no age restriction in the approved label.
The dosing difference: every 6–8 weeks vs. every 4–8
The headline difference between Befrena and Cytopoint is duration. Cytopoint's approved dosing interval is every four to eight weeks. In practice, many dogs need a shot closer to the four-week mark, especially during peak allergy season. Befrena's label dosing is every six to eight weeks — which Elanco is positioning as a real-world advantage for owners who'd rather make six trips a year to the clinic than ten.
How effective is the existing standard? A long-term study of Cytopoint published in BMC Veterinary Research found that 65% of atopic dogs saw meaningful itch reduction after one injection, climbing to 85% after two and 93% after three. Side effects were mostly mild — occasional vomiting, sleepiness, or injection-site soreness. About 2.5% of dogs eventually developed antibodies that made the medication stop working, which is one of the reasons vets have wanted another option in the same class.
Befrena's full peer-reviewed efficacy data hasn't been broadly published yet, so head-to-head comparisons will take time. What's clear from the USDA filing is that Elanco demonstrated effectiveness across a 6-to-8-week window in dogs of any age. Reported common side effects in clinical trials were vomiting, diarrhea, and tiredness; the label also notes that benign and malignant neoplastic conditions were observed during studies — a typical disclosure for biologics in this class, but worth discussing with your vet, especially for dogs with known cancer risk factors.
Where Befrena is most likely to fit in
If your dog already does well on Cytopoint, there's no urgency to swap. The honest takeaway from the available data is that Befrena is most interesting for dogs in two camps: those whose Cytopoint shots have started losing effectiveness over time (the small percentage who develop antibodies to lokivetmab), and those whose itch returns reliably before week six and would benefit from a longer-lasting alternative.
Some questions worth bringing to your next vet visit:
- Is Befrena available at your clinic yet, and if not, when?
- Is the price per shot in line with Cytopoint, or materially different?
- For dogs with severe year-round itch, is there a multimodal plan — antibody plus medicated baths, omega-3s, and allergen-specific immunotherapy — that beats either drug alone?
- Given your dog's age and health history, are there any cautions in the label that apply specifically to your pup?
Pet care decisions are pretty personal, and "what worked best for our last dog" is rarely the right answer for the new one. A good vet will walk you through the trade-offs based on your dog's history, breed risk, and how their current treatment is actually performing.
The bigger picture
Befrena's arrival is a sign of a broader shift: canine dermatology is finally getting the kind of pharmaceutical investment that human dermatology has had for years. Elanco itself launched Zenrelia (ilunocitinib), an oral JAK inhibitor, less than 18 months before Befrena's approval. That's two new prescription itch options in under two years from a single company — and Zoetis (the maker of Cytopoint and Apoquel) is actively running its own pipeline.
For dogs with atopic dermatitis, "we just put up with it" is becoming less and less of a default answer. The choice is increasingly between competing modern options, not between a modern option and nothing.
Watching this story
We'll keep tracking real-world feedback as Befrena reaches more clinics this spring and summer — including pricing, availability, and how veterinary dermatologists are choosing between Befrena, Cytopoint, Zenrelia, and Apoquel for different dogs. If your dog is one of the millions who scratches through every pollen season, this is a story worth following.
For more on what's behind the worst itching seasons of the year, our recent piece on spring allergies in dogs has the full breakdown — including the at-home steps that make any prescription work better.
